Literature DB >> 9923650

Hyperhomocysteinemia induces elastolysis in minipig arteries: structural consequences, arterial site specificity and effect of captopril-hydrochlorothiazide.

P Charpiot1, A Bescond, T Augier, C Chareyre, M Fraterno, P H Rolland, D Garçon.   

Abstract

Hyperhomocysteinemia is a risk factor for arterial diseases, and the deterioration of the arterial elastic structures is one of the possible mechanisms underlying this epidemiological association. The aim of this paper is to quantitatively characterize such structural alterations and to explore their causes in a previous model of dietary induced mild hyperhomocysteinemia in minipigs. After four months, both a morphodensitometrical analysis of the elastic structure and a biochemical analysis of elastin and elastase activities were performed on the infrarenal abdominal aorta (IRAA) and the proximal left interventricular coronary artery (LIVCA) of control (C), hyperhomocysteinemic (H) and captopril-hydrochlorothiazide (Cp-Htz, 25 + 12.5 mg/d)-treated (H+/-Cp) minipigs (n = 8/group). Hyperhomocysteinemia was found to induce an increase in parietal elastolytic metalloproteinase activities. It resulted in opening and enlargement of fenestrae through the medial elastic laminae and in a decrease in medial elastin content (p < 10(-3)), expressed as well as volume density (%) as weight concentration (microg elastin/mg dry tissue). The thickness of the media and its basic lamellar organization was unchanged. The reduction in volume density was more dramatic in LIVCA (H: 4.7 +/- 0.9 vs C: 8.8 +/- 2.4), where it was evenly distributed within the media, than in IRAA (H: 6.7 +/- 1.1 vs C: 9.3 +/- 1.2), where the deep medial layers were less affected. Cp-Htz partly prevented the hyperhomocysteinemia-induced reduction of the medial elastin content in LIVCA (5.7 +/- 1.2) and IRAA (7.9 +/- 1.4). This effect, occurring in the subintimal layers of the media in both arteries but not in the deeper layers, resulted in a less beneficial effect in LIVCA than in IRAA. This result parallels the moderate beneficial therapeutic effect of ACE inhibitors against coronary atherosclerosis in humans. This paper reports for the first time a quantitative analysis of the arterial site-dependent deterioration of the elastic structure caused by mild hyperhomocysteinemia and the involvement of metalloproteinases in this process. These results confirm that the plaque-independent damage to elastic structure previously described in hyperhomocysteinemic-atherosclerotic minipigs was mainly due to homocysteine. This highlights that the metalloproteinase-related elastolysis and the subsequent structural deterioration is one of the major events underlying the epidemiological association between mild hyperhomocysteinemia and arterial diseases.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9923650     DOI: 10.1016/s0945-053x(98)90108-1

Source DB:  PubMed          Journal:  Matrix Biol        ISSN: 0945-053X            Impact factor:   11.583


  12 in total

1.  TGFBR2 mutation and MTHFR-C677T polymorphism in a Mexican mestizo population with cervico-cerebral artery dissection.

Authors:  Angélica Ruiz-Franco; Miguel A Barboza; Aurelio Jara-Prado; Samuel Canizales-Quinteros; Paola Leon-Mimila; Nayelli Arguelles-Morales; Juan-Camilo Vargas-González; Alejandro Quiroz-Compean; Antonio Arauz
Journal:  J Neurol       Date:  2016-03-26       Impact factor: 4.849

2.  Homocysteine and nitric oxide levels in plasma of patients with pseudoexfoliation syndrome, pseudoexfoliation glaucoma, and primary open-angle glaucoma.

Authors:  Ozgül Altintaş; Hale Maral; Nurşen Yüksel; V Levent Karabaş; Meltem O Dillioğlugil; Yusuf Cağlar
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-02-02       Impact factor: 3.117

3.  Automated measurement and statistical modelling of elastic laminae in arteries.

Authors:  Hai Xu; Jin-Jia Hu; Jay D Humphrey; Jyh-Charn Liu
Journal:  Comput Methods Biomech Biomed Engin       Date:  2010-12       Impact factor: 1.763

4.  Functional consequences of homocysteinylation of the elastic fiber proteins fibrillin-1 and tropoelastin.

Authors:  Dirk Hubmacher; Judith T Cirulis; Ming Miao; Fred W Keeley; Dieter P Reinhardt
Journal:  J Biol Chem       Date:  2009-11-04       Impact factor: 5.157

5.  Homocysteine modulates the proteolytic potential of human arterial smooth muscle cells through a reactive oxygen species dependant mechanism.

Authors:  Xue Dan Ke; Alexandrine Foucault-Bertaud; Cecile Genovesio; Francoise Dignat-George; Edouard Lamy; Philippe Charpiot
Journal:  Mol Cell Biochem       Date:  2009-09-29       Impact factor: 3.396

6.  Plasma Homocysteine is a Predictive Factor for Arterial Stiffness: A Community-Based 4.8-Year Prospective Study.

Authors:  Xiao-Na Wang; Ping Ye; Rui-Hua Cao; Xu Yang; Wen-Kai Xiao; Yun Zhang; Yong-Yi Bai; Hong-Mei Wu
Journal:  J Clin Hypertens (Greenwich)       Date:  2015-04-20       Impact factor: 3.738

7.  Arterial function of carotid and brachial arteries in postmenopausal vegetarians.

Authors:  Ta-Chen Su; Pao-Ling Torng; Jiann-Shing Jeng; Ming-Fong Chen; Chiau-Suong Liau
Journal:  Vasc Health Risk Manag       Date:  2011-08-23

8.  Associations between plasma homocysteine levels, aortic stiffness and wave reflection in patients with arterial hypertension, isolated office hypertension and normotensive controls.

Authors:  G Vyssoulis; E Karpanou; S-M Kyvelou; D Adamopoulos; T Gialernios; E Gymnopoulou; D Cokkinos; C Stefanadis
Journal:  J Hum Hypertens       Date:  2009-06-11       Impact factor: 3.012

9.  Association between serum homocysteine and arterial stiffness in elderly: a community-based study.

Authors:  Song Zhang; Yong-Yi Bai; Lei-Ming Luo; Wen-Kai Xiao; Hong-Mei Wu; Ping Ye
Journal:  J Geriatr Cardiol       Date:  2014-03       Impact factor: 3.327

10.  Is there a causal role for homocysteine concentration in blood pressure? A Mendelian randomization study.

Authors:  Maria C Borges; Fernando P Hartwig; Isabel O Oliveira; Bernardo L Horta
Journal:  Am J Clin Nutr       Date:  2015-12-16       Impact factor: 7.045

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.